This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (343)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Review  • Alert me on articles by topic  Social Bookmarking   What's this?

Scientific Review

Silvio E. Inzucchi, MD

JAMA. 2002;287:360-372.

Context  Care of patients with type 2 diabetes has been revolutionized throughout the past several years—first, by the realization of the importance of tight glycemic control in forestalling complications, and second, by the availability of several unique classes of oral antidiabetic agents. Deciphering which agent to use in certain clinical situations is a new dilemma facing the primary care physician.

Objective  To systematically review available data from the literature regarding the efficacy of oral antidiabetic agents, both as monotherapy and in combination.

Data Sources  A MEDLINE search was performed to identify all English-language reports of unique, randomized controlled clinical trials involving recently available oral agents for type 2 diabetes. Bibliographies were also reviewed to find additional reports not otherwise identified.

Study Selection and Data Extraction  Studies (63) were included in the analysis if they had a study period of at least 3 months; if each group contained at least 10 subjects at the study's conclusion; and if hemoglobin A_1c was reported. When multiple dosages of a drug were tested, the results of the highest approved dosage were used. In placebo-controlled trials, hemoglobin A_1c data are presented as the difference between the change in treated vs placebo subjects.

Data Synthesis  Five distinct oral drug classes are now available for the treatment of type 2 diabetes. Compared with placebo treatment, most of these agents lower hemoglobin A_1c levels approximately 1% to 2%. Equivalent efficacy is usually demonstrated when different agents are compared with one another in the same study population. When they are used in combination, there are additional glycemic benefits. Long-term vascular risk reduction has been demonstrated only with sulfonylureas and metformin.

Conclusions  With few exceptions, the available oral antidiabetic agents are equally effective at lowering glucose concentrations. Their mechanisms of action are different, however, and as a result they appear to have distinct metabolic effects. These are reflected in their adverse effect profiles and their effect on cardiovascular risk, which may influence drug choice.

Author Affiliation: Section of Endocrinology, Yale University School of Medicine, New Haven, Conn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Drug Therapy for Patients With Type 2 Diabetes
John M. Poothullil, Nasser Mikhail, and Silvio E. Inzucchi
JAMA. 2002;287(13):1645-1646.
EXTRACT | FULL TEXT  

Treatment Decisions for Type 2 Diabetes
Mayer B. Davidson and Eric S. Holmboe
JAMA. 2002;287(13):1646-1648.
EXTRACT | FULL TEXT  

The Costs of Making Practice More Cost-effective
William B. Weeks, Amy E. Wallace, Michael A. Steinman, Ronald M. Epstein, David Lyman, James Mason, Martin Eccles, Nick Freemantle, Irwin Nazareth, Andrew Haines, and Michael Drummond
JAMA. 2002;287(13):1648-1650.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Oral Antihyperglycemic Therapy for Type 2 Diabetes: Clinical Applications
Eric S. Holmboe
JAMA. 2002;287(3):373-376.
ABSTRACT | FULL TEXT  

Scientific Review and Clinical Applications
Wendy Levinson and Catherine D. DeAngelis
JAMA. 2002;287(3):379.
EXTRACT | FULL TEXT  

January 16, 2002
JAMA. 2002;287(3):387-388.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
Lund et al.
BMJ 2009;339:b4324-b4324.
ABSTRACT | FULL TEXT  

In Vivo Metabolic Phenotyping of Myocardial Substrate Metabolism in Rodents: Differential Efficacy of Metformin and Rosiglitazone Monotherapy
Shoghi et al.
Circ Cardiovasc Imaging 2009;2:373-381.
ABSTRACT | FULL TEXT  

Review article: Diabetes mellitus and heart failure -- an overview of epidemiology and management
Baliga and Sapsford
Diabetes and Vascular Disease Research 2009;6:164-171.
ABSTRACT  

Dapagliflozin for the Treatment of Type 2 Diabetes
Brooks and Thacker
The Annals of Pharmacotherapy 2009;43:1286-1293.
ABSTRACT | FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Clin. Diabetes 2009;27:4-16.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Spectr. 2009;22:6-17.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2009;32:193-203.
ABSTRACT | FULL TEXT  

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus
Kothare et al.
J Clin Pharmacol 2008;48:1389-1399.
ABSTRACT | FULL TEXT  

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
Huttner et al.
J Clin Pharmacol 2008;48:1171-1178.
ABSTRACT | FULL TEXT  

Multidisciplinary Interventions: Mapping New Horizons in Diabetes Care
Horton et al.
The Diabetes Educator 2008;34:78S-89S.
ABSTRACT | FULL TEXT  

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
Lund et al.
Eur J Endocrinol 2008;158:631-641.
ABSTRACT | FULL TEXT  

The Case for Treating Tobacco Dependence as a Chronic Disease
Steinberg et al.
ANN INTERN MED 2008;148:554-556.
ABSTRACT | FULL TEXT  

New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
McGuire and Inzucchi
Circulation 2008;117:440-449.
FULL TEXT  

Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
Basu et al.
Diabetes 2008;57:24-31.
ABSTRACT | FULL TEXT  

Themed Review: Lifestyle Interventions Across the Continuum of Type 2 Diabetes: Reducing the Risks of Diabetes
Franz
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:327-334.
ABSTRACT  

Exercise reverses high-fat diet-induced impairments on compartmentalization and activation of components of the insulin-signaling cascade in skeletal muscle
Yaspelkis et al.
Am. J. Physiol. Endocrinol. Metab. 2007;293:E941-E949.
ABSTRACT | FULL TEXT  

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus
Bolen et al.
ANN INTERN MED 2007;147:386-399.
ABSTRACT | FULL TEXT  

Using diffusion of innovations theory to guide diabetes management program development: an illustrative example
De Civita and Dasgupta
J Public Health (Oxf) 2007;29:263-268.
ABSTRACT | FULL TEXT  

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes
Goldstein et al.
Diabetes Care 2007;30:1979-1987.
ABSTRACT | FULL TEXT  

Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus
Pham et al.
J Clin Pharmacol 2007;47:890-903.
ABSTRACT | FULL TEXT  

Tissue-Specific Effects of Rosiglitazone and Exercise in the Treatment of Lipid-Induced Insulin Resistance
Lessard et al.
Diabetes 2007;56:1856-1864.
ABSTRACT | FULL TEXT  

Clinical Translation of "A Diabetes Outcome Progression Trial": ADOPT Appropriate Combination Oral Therapies in Type 2 Diabetes
Goldstein
J. Clin. Endocrinol. Metab. 2007;92:1226-1228.
FULL TEXT  

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin
Gangji et al.
Diabetes Care 2007;30:389-394.
ABSTRACT | FULL TEXT  

Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects
Krishna et al.
J Clin Pharmacol 2007;47:165-174.
ABSTRACT | FULL TEXT  

Thiazolidinediones for Initial Treatment of Type 2 Diabetes?
Nathan
NEJM 2006;355:2477-2480.
FULL TEXT  

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
Aschner et al.
Diabetes Care 2006;29:2632-2637.
ABSTRACT | FULL TEXT  

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
Charbonnel et al.
Diabetes Care 2006;29:2638-2643.
ABSTRACT | FULL TEXT  

Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus
Koski
The Diabetes Educator 2006;32:869-876.
ABSTRACT | FULL TEXT  

Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy: A meta-regression analysis.
Bloomgarden et al.
Diabetes Care 2006;29:2137-2139.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2006;29:1963-1972.
FULL TEXT  

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects.
Herman et al.
J Clin Pharmacol 2006;46:876-886.
ABSTRACT | FULL TEXT  

Narrative Review: A Rational Approach to Starting Insulin Therapy
Mooradian et al.
ANN INTERN MED 2006;145:125-134.
ABSTRACT | FULL TEXT  

Review: Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes
Pratley et al.
British Journal of Diabetes & Vascular Disease 2006;6:150-156.
ABSTRACT  

Peroxisome proliferator-activated receptor gamma agonists in renal disease.
Iglesias and Diez
Eur J Endocrinol 2006;154:613-621.
ABSTRACT | FULL TEXT  

Treatment Escalation and Rise in HbA1c Following Successful Initial Metformin Therapy.
Nichols et al.
Diabetes Care 2006;29:504-509.
ABSTRACT | FULL TEXT  

Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock et al.
Diabetes Care 2006;29:554-559.
ABSTRACT | FULL TEXT  

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
Simpson et al.
CMAJ 2006;174:169-174.
ABSTRACT | FULL TEXT  

A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus
Shea et al.
J. Am. Med. Inform. Assoc. 2006;13:40-51.
ABSTRACT | FULL TEXT  

Diabetes in African Americans
Marshall
Postgrad. Med. J. 2005;81:734-740.
ABSTRACT | FULL TEXT  

Medications Associated with Weight Gain
Malone
The Annals of Pharmacotherapy 2005;39:2046-2054.
ABSTRACT | FULL TEXT  

Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial
Rosenstock et al.
ANN INTERN MED 2005;143:549-558.
ABSTRACT | FULL TEXT  

The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes
Strowig and Raskin
Diabetes Care 2005;28:1562-1567.
ABSTRACT | FULL TEXT  

Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes
Green et al.
British Journal of Diabetes & Vascular Disease 2005;5:134-140.
ABSTRACT  

Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Cook et al.
Diabetes Care 2005;28:995-1000.
ABSTRACT | FULL TEXT  

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
Kendall et al.
Diabetes Care 2005;28:1083-1091.
ABSTRACT | FULL TEXT  

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes
DeFronzo et al.
Diabetes Care 2005;28:1092-1100.
ABSTRACT | FULL TEXT  

Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin-4) in Healthy Subjects
Blase et al.
J Clin Pharmacol 2005;45:570-577.
ABSTRACT | FULL TEXT  

Oral Agents for Type 2 Diabetes: An Update
Kimmel and Inzucchi
Clin. Diabetes 2005;23:64-76.
ABSTRACT | FULL TEXT  

Oral antihyperglycemic therapy for type 2 diabetes mellitus
Cheng and Fantus
CMAJ 2005;172:213-226.
ABSTRACT | FULL TEXT  

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Kolterman et al.
Am J Health Syst Pharm 2005;62:173-181.
ABSTRACT | FULL TEXT  

Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
Gross et al.
Diabetes Care 2005;28:164-176.
ABSTRACT | FULL TEXT  

Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms
Erbe et al.
Mol. Pharmacol. 2005;67:69-77.
ABSTRACT | FULL TEXT  

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
Buse et al.
Diabetes Care 2004;27:2628-2635.
ABSTRACT | FULL TEXT  

Pounds Off With Empowerment (POWER): A Clinical Trial of Weight Management Strategies for Black and White Adults With Diabetes Who Live in Medically Underserved Rural Communities
Mayer-Davis et al.
AJPH 2004;94:1736-1742.
ABSTRACT | FULL TEXT  

Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Strowig et al.
Diabetes Care 2004;27:1577-1583.
ABSTRACT | FULL TEXT  

Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study
Rosenstock et al.
Diabetes Care 2004;27:1265-1270.
ABSTRACT | FULL TEXT  

Understanding the rising incidence of type 2 diabetes in adolescence
Weill et al.
Arch. Dis. Child. 2004;89:502-504.
FULL TEXT  

Pharmacy Costs and Glycemic Control in the Department of Veterans Affairs
Weinstock et al.
Diabetes Care 2004;27:B74-B81.
ABSTRACT | FULL TEXT  

Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study: Response to Delea et al.
Karter et al.
Diabetes Care 2004;27:850-851.
FULL TEXT  

Self-monitoring Blood Glucose (SMBG): Now and the Future
Briggs and Cornell
Journal of Pharmacy Practice 2004;17:29-38.
ABSTRACT  

Oral Antidiabetic Agents: A Comparative Review
Koski
Journal of Pharmacy Practice 2004;17:39-48.
ABSTRACT  

Glycemic Index in the Treatment of Diabetes: The Debate Continues
Sievenpiper and Vuksan
J. Am. Coll. Nutr. 2004;23:1-4.
FULL TEXT  

Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah et al.
JAMA 2004;291:335-342.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator Activator Receptor-{gamma} Ligands, 15-Deoxy-{Delta}12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways
Zingarelli et al.
J. Immunol. 2003;171:6827-6837.
ABSTRACT | FULL TEXT  

Update on diabetes diagnosis and management
ROBERTSON et al.
Journal of the American Dental Association 2003;134:16S-23S.
ABSTRACT | FULL TEXT  

Insulin 70/30 Mix Plus Metformin Versus Triple Oral Therapy in the Treatment of Type 2 Diabetes After Failure of Two Oral Drugs: Efficacy, safety, and cost analysis
Schwartz et al.
Diabetes Care 2003;26:2238-2243.
ABSTRACT | FULL TEXT  

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes
Fineman et al.
Diabetes Care 2003;26:2370-2377.
ABSTRACT | FULL TEXT  

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes
Kolterman et al.
J. Clin. Endocrinol. Metab. 2003;88:3082-3089.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Combination Therapy: Repaglinide plus metformin versus nateglinide plus metformin
Raskin et al.
Diabetes Care 2003;26:2063-2068.
ABSTRACT | FULL TEXT  

Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach
Sheehan
Clin Med Res 2003;1:189-200.
ABSTRACT | FULL TEXT  

Recent Antihyperglycemic Prescribing Trends for U.S. Privately Insured Patients With Type 2 Diabetes
Cohen et al.
Diabetes Care 2003;26:1847-1851.
ABSTRACT | FULL TEXT  

Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt and Hirsch
JAMA 2003;289:2254-2264.
ABSTRACT | FULL TEXT  

Insulin Sensitizers
Zangeneh et al.
Mayo Clin Proc. 2003;78:471-479.
ABSTRACT  

Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle and Egan
Pharmacol. Rev. 2003;55:105-131.
ABSTRACT | FULL TEXT  

OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT  

Is Metformin Cardioprotective?
Sasali and Leahy
Diabetes Care 2003;26:243-244.
FULL TEXT  

Case Study: A Patient With Uncontrolled Type 2 Diabetes and Complex Comorbidities Whose Diabetes Care Is Managed by an Advanced Practice Nurse
Spollett
Diabetes Spectr. 2003;16:32-36.
FULL TEXT  

Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald et al.
JAMA 2002;288:2868-2879.
ABSTRACT | FULL TEXT  

Helping Patients Follow Prescribed Treatment: Clinical Applications
Haynes et al.
JAMA 2002;288:2880-2883.
ABSTRACT | FULL TEXT  

Review: Type 2 diabetes: how far have we come?
Lebovitz
British Journal of Diabetes & Vascular Disease 2002;2:446-449.
ABSTRACT  

Polypharmacy in Elderly Patients With Diabetes
Good
Diabetes Spectr. 2002;15:240-248.
ABSTRACT | FULL TEXT  

Kir6.2 is required for adaptation to stress
Zingman et al.
Proc. Natl. Acad. Sci. USA 2002;99:13278-13283.
ABSTRACT | FULL TEXT  

How Do the New Insulin Secretagogues Compare?
Cohen and Ramlo-Halsted
Diabetes Care 2002;25:1472-1473.
FULL TEXT  

Drug Therapy for Patients With Type 2 Diabetes
Poothullil et al.
JAMA 2002;287:1645-1646.
FULL TEXT  

Treatment Decisions for Type 2 Diabetes
Davidson and Holmboe
JAMA 2002;287:1646-1648.
FULL TEXT  

Cardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues
Caulfield and O'Brien
Clin. Diabetes 2002;20:81-84.
ABSTRACT | FULL TEXT  

Oral Antihyperglycemic Therapy for Type 2 Diabetes: Clinical Applications
Holmboe
JAMA 2002;287:373-376.
ABSTRACT | FULL TEXT  

Scientific Review and Clinical Applications
Levinson and DeAngelis
JAMA 2002;287:379-379.
FULL TEXT